News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Imugene.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX dips as AGL stalls; Talga skyrockets after Sweden approves graphite mine
Health & Biotech
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
News
Top 10 at 11: Robot sentries, big deals and exploration are today’s headline makers
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
News
Market Highlights: Nvidia loses top spot to Microsoft on ‘Triple Witching’ day, and 5 small caps to watch
Tech
From high-tech cancer fighters to AI-wielding crime busters, these are some of the most innovative firms on the ASX
Tech
Up close and personal with ASX tech and Biotech
Health & Biotech
ASX Health Stocks: Atomo sells more HIV Self-Tests; Actinogen begins Phase 2b trial on Alzheimer’s
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX resumes rally on Powell’s remarks; goldies in focus, copper hits 12-month high
News
Market Highlights: Powell’s speech to lift ASX today, and what Tesla’s bad quarter signals to investors
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Dimerix ACTION3 Phase 3 interim trial results are out… and they’re good
News
Market Highlights: Lyft stock jumps 35pc, the new Sensational Six, and 5 small caps to watch today
News
In Case You Missed It: A thing, a different thing and an amusing play on words, I guess
Health & Biotech
ASX Health Stocks: Imugene gains on positive early signs from Phase 1 trial
News
